SEC Form 4	
------------	--

Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287	
Estimated average burden		
hours per response:	0.5	

Filed pursuant to Section	16(a) of the Securities Exchange Act of 1934

or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol 1. Name and Address of Reporting Person* 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) SUPERNUS PHARMACEUTICALS, INC DEC TIMOTHY C Director 10% Owner [SUPN] Officer (give title Other (specify X below) below) 3. Date of Earliest Transaction (Month/Day/Year) (Last) (First) (Middle) Senior Vice-President & CFO 05/04/2023 C/O SUPERNUS PHARMACEUTICALS, INC. 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable 9715 KEY WEST AVENUE Line) Х Form filed by One Reporting Person (Street) Form filed by More than One Reporting ROCKVILLE 20850 MD Person Rule 10b5-1(c) Transaction Indication (City) (State) (Zip) Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 2. Transaction 2A. Deemed 5. Amount of 6. Ownership 7. Nature of 1. Title of Security (Instr. 3) Transaction Execution Date. Securities Form: Direct Indirect Beneficial (Month/Dav/Year) if any Code (Instr. 5) Beneficially (D) or Indirect (Month/Day/Year) 8) Owned Following Ownership (Instr. 4) (I) (Instr. 4) Reported (A) or (D) Transaction(s) Code v Amount Price (Instr. 3 and 4) Common Stock 1,859 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 5. Number 6. Date Exercisable and 1. Title of 3. Transaction 3A. Deemed 7. Title and 8. Price of 9. Number of 10. 11. Nature 2. Conversion Date Transaction Ownership Derivative Execution Date of Expiration Date Amount of Derivative derivative of Indirect Security (Instr. 3) or Exercise (Month/Day/Year) if any Code (Instr. Derivative (Month/Day/Year) Securities Security (Instr. 5) Securities Form: Beneficial Price of Derivative (Month/Day/Year) 8) Securitie Underlying Derivative Security Beneficially Direct (D) Ownership (Instr. 4) Acquired (A) or Disposed of (D) (Instr. 3, 4 Owned or Indirect Security (Instr. 3 and 4) Following (I) (Instr. 4) Reported Transaction(s) (Instr. 4) and 5) Amount Numbe Date Expiration of v (A) (D) Date Shares Code Exercisable Title Performance Commor 05/04/2023 1,500 1,500 1,500 \$<mark>0</mark> \$<mark>0</mark> D Α Share Units Stock

Explanation of Responses:

1. On May 3, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period.

/s/ Timothy C. Dec

<u>05/08/2023</u> Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.